drugset / Trial / NCT05836623
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
Non-randomizedSingle-groupOpen-labelTreatment
Summary
CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA) undergoing Phase 1 assessment in patients with PSMA+ solid tumours. This sub study will assess the biodistribution of radiolabelled CB307 in patients with advanced and/or metastatic solid tumours that are PSMA+.
Timeline
- Start
- 2022-12-20
- Primary completion
- 2024-01-31
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CB307 | Other / unclassified | 1 mg/ml | — |
| Subject | CB307 | Other / unclassified | 37 mbq | — |
| Subject | CB307 | Other / unclassified | — | — |
Indications
No indication recorded.